TH Global Capital Closes 4 Major M&A Deals in Australia in 4 Months Including the Sale of The Missing Link to Infosys
SYDNEY — TH Global Capital, an award-winning global boutique investment bank with a presence in 13 countries, has closed four high profile deals in the first four months of 2025, including the sale of The Missing Link to Infosys for 120 million AUD. This marks its tenth cross border transaction in Australia over the past 18 months, cementing its position as the mid-market M&A boutique investment bank of choice in Australia and New Zealand.
Article content
Sale of The Missing Link to Infosys – The Missing Link, an award-winning cybersecurity and IT services provider based in Sydney, will join Infosys to deliver cybersecurity solutions and expand Infosys's presence in Australia.
Sale of TMLabs to Coforge – TMLabs, a ServiceNow Elite partner and digital transformation leader headquartered in Sydney, strengthens Coforge's ServiceNow capabilities in Australia and leverages TMLabs' existing contracts.
Sale of Skie to Bluprintx – TH Global Capital's 13th transaction in ANZ and 12th Salesforce deal globally. Skie, a leading Salesforce consulting partner headquartered in Victoria, adds deep expertise to Bluprintx and strengthens its Salesforce capabilities in the APAC region.
Sale of PhoenixDX to Alan Allman Associates – PhoenixDX, a leading low-code product engineering firm based in Sydney, enhances France-based Alan Allman Associates' capabilities and service offerings across the APAC region.
Article content
Article content
Over the past 24 years, TH Global Capital has closed transactions with leading strategic buyers and private equity funds across 29 countries. Notable ANZ deals include:
Article content
Chamonix IT, a leading Digital Engineering and Microsoft partner, on its sale to Synechron
Exposé, a premier AI and Data Science company, on its sale to Synechron
Design + Industry, a world class MedTech Product Design and Engineering consultancy, on its sale to Capgemini
The Lumery, a leading MarTech consultancy, on its sale to Accenture
Leonardo, an Automation, BPM & Business Process Transformation specialist, on its sale to UST
DEK Technologies, a premier Software Engineering and Embedded Systems specialist, on its sale to Endava
Enable, a leading global ServiceNow partner, on its sale to Fujitsu
Tenzing, a Management and Technology consultancy, on its sale to Tech Mahindra
Article content
Vivek Subramanyam
Article content
, Founder and CEO of TH Global Capital, said, 'Our success in the ANZ region is a testament to our deep market knowledge and extensive global network of buyers and investors. We remain the trusted advisor of choice in the region and globally, committed to driving strategic transactions that create long-term value for our clients.'
Article content
, Director and Head of TMT, ANZ at TH Global Capital, added, 'The ANZ region is experiencing a surge in M&A activity, fuelled by innovation and strong investor appetite. We're proud to be at the forefront of this momentum, advising businesses and connecting them with the right capital and strategic partners globally.'
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Canada News.Net
2 hours ago
- Canada News.Net
American Eagle's ‘great jeans' campaign faces criticism over wordplay
NEW YORK CITY, New York: American Eagle Outfitters, a popular U.S. clothing brand, wanted to grab attention with its new fall advertising campaign featuring 27-year-old actress Sydney Sweeney. The campaign, built around bold and cheeky language, was designed to spark conversations, according to the company's chief marketing officer. It has done just that — but not always in the way the company might have hoped. The campaign is titled " Sydney Sweeney has great jeans." Some ads used wordplay, swapping "jeans" with "genes," a reference to Sweeney's blonde hair and blue eyes. This caused a backlash. Critics said the word choice seemed to echo ideas linked to eugenics, a discredited theory that claimed humanity could be "improved" through selective breeding for specific physical traits. Marcus Collins, a marketing professor at the University of Michigan, said the campaign might not have faced such criticism if it had featured models of different races making the same pun. "This could be seen as ignorance, laziness, or intentional," he said. "None of those options are good." Other voices defended the campaign and dismissed the backlash as an overreaction. Former Fox News host Megyn Kelly wrote on X (formerly Twitter) that critics were only giving Sweeney more publicity, saying the controversy had "only resulted in a beautiful white blonde girl with blue eyes getting 1000x the exposure for her 'good genes.'" American Eagle has not responded publicly to the criticism. The controversy comes at a challenging time for the retailer. Like many fashion brands, American Eagle is struggling with weaker consumer spending and higher costs due to tariffs. Sales for the February-to-April quarter fell five percent compared to last year. However, when Sweeney's partnership was announced, the company's stock rose more than four percent in one day. By midweek this week, shares had fallen again, trading nearly two percent lower. Experts say the company's strategy is not unusual. Alan Adamson, co-founder of marketing firm Metaforce, explained that clothing brands often try to stand out with bold campaigns. He compared the Sweeney ads to Calvin Klein's famous 1980 commercials featuring 15-year-old Brooke Shields, which sparked controversy over suggestive wording. "It's the same playbook: a beautiful model saying provocative things, shot in an eye-catching way," Adamson said. American Eagle's chief marketing officer Craig Brommers described Sweeney as "the biggest get in the history of American Eagle" in an interview with industry site Retail Brew. He said the company wanted to promote her partnership in a big, bold way. The campaign includes videos of Sweeney in relaxed-fit jeans, digital billboards in places like Times Square, social media appearances on Snapchat and Instagram, and even an AI-powered feature that lets shoppers virtually try on jeans. The company is also releasing a special limited-edition "Sydney" jean, with part of the sales going to a nonprofit that provides crisis counseling for domestic violence victims. In its press release, American Eagle described Sweeney's appeal as a mix of "girl-next-door charm" and "main character energy," adding that her playful personality made her the perfect fit for the campaign.
Globe and Mail
8 hours ago
- Globe and Mail
Vivid Seats Announces Reverse Stock Split
CHICAGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vivid Seats Inc. (NASDAQ: SEAT) ('Vivid Seats'), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced a 1-for-20 reverse stock split of its Class A and Class B common stock (the 'Reverse Stock Split'), effective at 5:00 p.m. Eastern Time on August 5, 2025. The Class A common stock will begin trading on the Nasdaq Global Select Market on a split-adjusted basis under the existing ticker symbol 'SEAT' when the market opens on August 6, 2025. The new CUSIP number for the Class A common stock following the Reverse Stock Split is 92854T209. The Reverse Stock Split was approved by Vivid Seats' stockholders on July 21, 2025, with the final ratio subsequently determined by Vivid Seats' Board of Directors. As a result of the Reverse Stock Split, every 20 shares of common stock will automatically be combined into one share of common stock. Class A stockholders who would otherwise be entitled to receive a fractional share will instead be entitled to receive, in lieu thereof, a cash payment. The Reverse Stock Split will not affect any stockholder's percentage ownership interest or voting power in Vivid Seats, other than as a result of the treatment of fractional shares. All of Vivid Seats' outstanding warrants, including its public warrants trading on the Nasdaq Global Select Market under the ticker symbol 'SEATW,' and equity-based awards will be proportionately adjusted (including applicable exercise prices) in accordance with their respective terms. Vivid Seats' transfer agent, Continental Stock Transfer & Trust Company, is acting as the exchange agent for the Reverse Stock Split. Stockholders who hold their shares electronically in book-entry form will receive a transaction statement indicating the number of shares held after the Reverse Stock Split, along with a cash payment in lieu of any fractional shares. Stockholders who hold their shares through a bank, broker, or other nominee will have their positions adjusted to reflect the Reverse Stock Split, and receive a cash payment in lieu of any fractional shares, in accordance with the processes of their respective bank, broker, or nominee. More information regarding the Reverse Stock Split can be found in Vivid Seats' definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on July 11, 2025. About Vivid Seats Founded in 2001, Vivid Seats is a leading online ticket marketplace committed to becoming the ultimate partner for connecting fans to the live events, artists, and teams they love. Based on the belief that everyone should ' Experience It Live,' the Chicago-based company provides exceptional value by providing one of the widest selections of events and tickets in North America and an industry leading Vivid Seats Rewards program where all fans earn on every purchase. Through its proprietary software and unique technology, Vivid Seats drives the consumer and business ecosystem for live event ticketing and enables the power of shared experiences to unite people. Vivid Seats has been recognized by Newsweek as one of America's Best Companies for Customer Service in ticketing. Fans who want to have the best live experiences can start by downloading the Vivid Seats mobile app, going to or calling 866-848-8499. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Words such as 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'design,' 'estimate,' 'expect,' 'forecast,' 'future,' 'goal,' 'intend,' 'likely,' 'may,' 'plan,' 'project,' 'propose,' 'seek,' 'should,' 'target,' 'will,' and 'would,' as well as similar expressions which predict or indicate future events and trends or which do not relate to historical matters, are intended to identify such forward-looking statements. The forward-looking statements in this press release relate to, without limitation, the timing of the Reverse Stock Split and its impact on Vivid Seats' stockholders. Forward-looking statements are not guarantees of future performance, conditions, or results, and are subject to risks, uncertainties, and assumptions that can be difficult to predict and/or are outside of Vivid Seats' control. Therefore, actual results may differ materially from those contemplated by any forward-looking statements. Important factors that could cause or contribute to such differences include, but are not limited to, Vivid Seats' ability to implement the Reverse Stock Split on the anticipated timing or at all, Vivid Seats' ability to achieve the anticipated benefits of the Reverse Stock Split, and other factors discussed in the 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' sections of Vivid Seats' most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, Vivid Seats undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Contacts: Investors Kate Africk Media Julia Young
National Post
11 hours ago
- National Post
Nucleus Network Acquires Hammersmith Medicines Research
Article content BRISBANE, Australia & LONDON — Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom's most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network's global growth, establishing the only early phase provider with dedicated facilities in Australia, the United States, and the United Kingdom. Article content The acquisition brings together two organisations with a shared mission: advancing medicine and improving lives. It also honours the legacy of Dr Malcolm Boyce, whose leadership established HMR as a centre of excellence in early phase research across the UK and Europe. With complementary scientific expertise and a strong, mutual commitment to participant safety and ethical conduct, the combined organisation is well positioned to accelerate clinical development and deliver inclusive, high-quality studies across three continents. Article content 'We are deeply honoured by the trust Dr Boyce has placed in us to carry forward HMR's legacy,' said Article content . 'This acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture, and purpose. Together, we are building a platform that will help redefine the way early phase trials are delivered.' Article content A New Standard for Early-Phase Clinical Trials Article content With the acquisition of HMR, Nucleus Network is setting a new global benchmark in the delivery of early-phase clinical trials. Sponsors now benefit from a fully integrated model that combines global reach with deep local expertise. By harnessing the strength of our globally leading and multi-jurisdictional business development team, we will work in close partnership with sponsors to guide trials to the geographic locations that best align with their strategic priorities. Studies can commence in one regulatory environment and seamlessly transition to another, enabled by harmonised processes and consistently high-quality standards, accelerating timelines and reducing operational risk. Article content The expanded geographic footprint expands access to broader and more diverse volunteer and patient populations. This scale supports faster recruitment and more inclusive study designs, both of which are critical for first-in-human and adaptive trial protocols. HMR's decades of scientific and operational excellence complement Nucleus Network's advanced infrastructure and digital capabilities. Together, they bring added precision to study execution and data quality, driving robust outcomes across all sites. Article content Sponsors will experience more streamlined engagement through unified systems, shared best practices, and coordinated project delivery, simplifying the complexities of early-phase trial execution. This integration further strengthens Nucleus Network's position as the most experienced global provider dedicated to early-phase clinical research. Article content At the same time, Nucleus Network will continue to partner with CROs around the world, offering flexible services that complement existing partnerships and extend reach across geographies. Article content ' This acquisition expands what's possible for our sponsors,' Pisarev added. 'It deepens our scientific capabilities, strengthens our operational reach, and reinforces our commitment to delivering life-changing therapies to patients around the world.' Nucleus Network will continue to operate its clinical sites in Brisbane, Melbourne, and Sydney (from ~2026), Australia; Minneapolis, Minnesota; and London, England, ensuring continuity for ongoing studies and trusted relationships. Article content Nucleus Network is the only early-phase clinical research provider with a global footprint, operating dedicated Phase I facilities in Australia, the United States, and the United Kingdom. With over 20 years of experience and more than 1,500 first-in-human studies conducted, Nucleus Network is recognized for its scientific excellence, operational integrity, and commitment to innovation. Article content Article content Article content Article content Contacts Article content Media Contact Article content
